OMERS ADMINISTRATION Corp Takes $1.44 Million Position in Krystal Biotech, Inc. $KRYS

OMERS ADMINISTRATION Corp purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 3,880 shares of the company’s stock, valued at approximately $1,442,000.

Several other large investors have also recently added to or reduced their stakes in KRYS. Royal Bank of Canada boosted its holdings in Krystal Biotech by 145.2% in the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock valued at $294,000 after purchasing an additional 964 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Krystal Biotech by 29.9% during the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after buying an additional 2,792 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Krystal Biotech by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock worth $2,870,000 after buying an additional 688 shares in the last quarter. Empowered Funds LLC acquired a new stake in shares of Krystal Biotech in the 1st quarter valued at approximately $218,000. Finally, Cetera Investment Advisers lifted its holdings in shares of Krystal Biotech by 107.9% in the 2nd quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock valued at $597,000 after buying an additional 2,255 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Dino A. Rossi sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the transaction, the director directly owned 50,000 shares in the company, valued at $16,456,000. The trade was a 33.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the sale, the insider directly owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,000 shares of company stock worth $16,278,020 over the last ninety days. 13.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

KRYS has been the topic of a number of analyst reports. Chardan Capital upgraded Krystal Biotech to a “strong-buy” rating in a research note on Monday, August 3rd. TD Cowen increased their price objective on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. Bank of America raised their target price on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Weiss Ratings lowered shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Finally, Citigroup upped their price target on shares of Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $365.40.

Krystal Biotech Stock Up 1.0%

Krystal Biotech stock opened at $359.76 on Thursday. Krystal Biotech, Inc. has a 52 week low of $136.73 and a 52 week high of $382.54. The firm’s 50-day simple moving average is $348.38 and its 200 day simple moving average is $303.24. The firm has a market capitalization of $10.65 billion, a PE ratio of 45.08 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, beating the consensus estimate of $1.70 by $0.09. The firm had revenue of $119.22 million during the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. On average, research analysts expect that Krystal Biotech, Inc. will post 7.68 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.